Stephen B. Howell
YOU?
Author Swipe
View article: Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 5
View article: Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Information on antibody RRID and Other catalog numbers
View article: Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 6
View article: Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 3
View article: Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 7
View article: Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Table file to be published with manuscript
View article: Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 8
View article: Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 4
View article: Suppl Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 2
View article: Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 1
View article: Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 8
View article: Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 3
View article: Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 4
View article: Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Information on antibody RRID and Other catalog numbers
View article: Suppl Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 2
View article: Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 6
View article: Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 1
View article: Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 7
View article: Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 5
View article: Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Table file to be published with manuscript
View article: Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 1
View article: Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Information on antibody RRID and Other catalog numbers
View article: Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 4
View article: Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Characterization of TUS/R MOLM-14 cell lines. A, Effect of TUS on the growth rate of parental MOLM-14 cells and four sublines selected for growth in 75 nmol/L TUS (P < 0.01 vs. MOLM-14 parental cells for all TUS/R lines). B, Change in TUS …
View article: Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 3
View article: Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Table file to be published with manuscript
View article: Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Structure of TUS and pattern of kinase inhibition. A, Structure of TUS. B, Principal kinases inhibited by TUS as determined from broad kinase screens.
View article: Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 5
View article: Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Effect of NRASG12D expression in MV-4-11 clones on sensitivity to (A) TUS and (B) VEN (data are mean ± SEM from three-independent experiments). C, Antitumor activity of TUS, belvarafenib, and the combination of both in mice bearing MV-4-11…
View article: Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 8